Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. (20th November 2020)

• Record Type: Journal Article
• Authors: Brook, Robert D; Kaciroti, Niko; Bakris, George; Dahlöf, Björn; Pitt, Bertrtam; Velazquez, Eric; Weber, Michael A; Jamerson, Kenneth A
• Is Part Of: American journal of hypertension. Volume 34:Number 5(2021)
• Page Start: 531
• Page End: 539
• Publication Date: 2020-11-20
• Subjects: blood pressure -- blood pressure targets -- drug therapy -- hypertension -- prevention; Hypertension -- Periodicals; 616.132005
• DOI: 10.1093/ajh/hpaa192
• Languages: English
• ISSNs: 0895-7061

Abstract

Abstract: BACKGROUND: The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to <130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI). METHODS: In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial ( n = 11, 506), we compared the primary composite outcome (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) between the 2 combination-treatment limbs in patients achieving a systolic BP ≤130 mm Hg and those with "apparent resistant hypertension" (prescribed ≥4 antihypertensive medications). RESULTS: Among study patients, 5, 221 (45.4%) achieved a systolic BP ≤130 mm Hg. There were fewer primary endpoints in the amlodipine/benazepril (9.2%) vs. the HCTZ/benazepril (10.9%) limb (adjusted hazard ratio [HR] 0.83, 95% confidence interval [CI], 0.70–0.99). There were also fewer primary endpoints in the amlodipine/benazepril (12.8%) vs. the HCTZ/benazepril (15.2%) limb ( n = 4, 451, 38.7%) among patients with apparent resistant hypertension (HR 0.81, 95% CI, 0.70–0.95). CONCLUSIONS: Combination therapy adding a CCB, rather than HCTZ, to an ACEI was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic BP targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination. CLINICAL TRIALS REGISTRATION: Trial Number NCT00170950.